Ischemic heart disease is the leading
cause of death in the United States1 and
angina pectoris is a common symptom of
this disease.2,3 "Angina" is used to describe
clinical symptoms such as discomfort in the
chest, jaw, shoulder, back, or arms that are
induced by physical exertion or emotional
stress and subside with rest or treatment
with nitroglycerin.4 Some patients do not experience
discomfort but complain of breathlessness
or tire with activity. These symptoms
are the result of underlying myocardial
ischemia and are sometimes called anginal
equivalents.
The American Heart Association (AHA)
estimates that 6.8 million Americans suffer
from angina and that 400 000 new patients
present with stable angina each year.1
Significantly more women have the condition
than men, both in total numbers and as
an age-adjusted percentage.1 Angina limits
normal daily activities; thus, it has a negative
impact on quality of life (QOL). It has been
shown that 1 year after coronary revascularization,
roughly one third of patients with
angina are not able to return to work.5 Not
surprisingly, the societal impact and economic
costs of angina are staggering. In the American
College of Cardiology (ACC)/AHA 2002
Guideline Update for the Management of Patients
with Chronic Stable Angina, Gibbons
and colleagues state, "angina affects many
millions of Americans with associated annual
costs that are measured in tens of billions
of dollars."4
Angina treatment involves a number of
strategies.4 In general, the first step in angina
management includes assessing patient
risk factors, such as smoking, hypertension,
dyslipidemia, diabetes mellitus, obesity, and
physical inactivity. While alterations in these
risk factors may improve symptoms and
reduce cardiac events, the majority of patients
with chronic stable angina require
specific antianginal medications. It is recommended
that beta-adrenergic blocking drugs
be used as first-line therapy for patients with
angina because these agents have been shown
to have cardioprotective effects.4 Other standard
therapies for chronic angina include
calcium channel blocking agents and organic
nitrates,4 but such medical therapy often
does not provide adequate symptomatic relief.
A number of novel therapies are directed
at angina treatment, including new pharmacologic
agents, gene therapy, enhanced external
counterpulsation (EECP), spinal cord
stimulation, and innovations in revascularization
therapy. This article reviews the
classification of angina pectoris and briefly
describes standard and novel treatment
strategies for this debilitating health problem.
Understanding Angina. Whereas there has
been considerable research regarding angina,
the exact mechanism of pain perception in
patients with myocardial ischemia is still
poorly understood. However, cardiac ischemic
discomfort may be perceived in the heart,
chest wall, arms, and back because of the
close proximity of the spinal nerve receptors
to these areas.6 Chest pain caused by
myocardial ischemia is classified as stable or
unstable angina.4 Patients with unstable angina
have a much higher risk of acute cardiac
events than patients with stable angina pectoris.
Such risk can be further stratified as
low, moderate, or high, depending on the frequency
and severity of pain and on the presence
of certain electrocardiographic
abnormalities. Unstable angina is commonly
described based on the way it presents. This
includes new onset angina or angina that has
increased in frequency and severity despite
medical therapy, or angina that occurs at rest
(Table 1). Angina is frequently defined using
Canadian Cardiovascular Society (CCS)
functional class (Table 2),7 a system that has
been used for more than 3 decades. In 2002,
a new CCS definition for grade IV angina was
suggested that includes a set of detailed activities,
"angina occurs while walking less than
1 blockā¦or while walking in the house, or
doing light chores or personal care" rather
than the previous description: "Inability to
carry on any physical activity without discomfort
anginal symptoms may be present
at rest."8 While other grading systems have
been defined, the CCS functional classification
has been the most widely used by clinicians
and investigators.


Treatment of Angina Pectoris. Decreasing
the frequency and severity of angina
improves QOL for patients with angina. Although
smoking cessation, weight control,
stress management, moderate exercise, and
appropriate management of hypertension,
dyslipidemia, and diabetes mellitus may
reduce symptoms and ischemic events,
pharmacotherapy with antianginal agents is
usually required. Beta-adrenergic blocking
agents, calcium channel blocking agents,
and short- and long-acting nitrates are the
foundation of medical therapy for patients
with chronic angina.4 Although each has a
different mechanism of action, these agents
have multiple effects that tend to decrease
cardiac workload and, therefore, lower myocardial
energy requirements and/or increase
coronary blood flow or improve its distribution.
These effects help lessen the mismatch
between myocardial oxygen requirements
and oxygen supply. Unfortunately, many
patients require more than 1 drug to control
symptoms,9 and patients with comorbid conditions
often require a host of other medications
as well. Indeed, a variety of agents,
including antiplatelet/antithrombotic agents,
angiotensin-converting enzyme inhibitors,
and lipid-lowering drugs, are important therapeutic
adjuncts in the treatment of patients
with chronic angina.4 Ultimately, the potential
for adverse drug interactions and side
effects associated with polypharmacy may
limit the ability of a patient with chronic angina
to tolerate appropriate medical therapy.